Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques

Journal of Virology

Volumn 83, Issue 10, 2009, Pages 5067-5076

  Dudley, Dawn M ^a,b   Wentzel, Jennifer L ^b   Lalonde, Matthew S ^a,b   Veazey, Ronald S ^c   Arts, Eric J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MICROBICIDE; RANTES; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RANTES, N(ALPHA) (N NONANOYL) DESSER(1) (THIOPROLINE(2),CYCLOHEXYLGLYCINE(3)); RANTES, N(ALPHA)-(N-NONANOYL)-DESSER(1)-(THIOPROLINE(2),CYCLOHEXYLGLYCINE(3))-; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INOCULATION; MACACA; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TISSUE CULTURE; VIRUS INFECTION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; ANTIVIRAL RESISTANCE; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; VAGINA; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTI-HIV AGENTS; CELLS, CULTURED; CHEMOKINE CCL5; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MUTATION; POLYMORPHISM, GENETIC; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA;

EID: 65349147003     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00055-09     Document Type: Article

References (41)

1. Ambrose, Z., V. Boltz, S. Palmer, J. M. Coffin, S. H. Hughes, and V. N. KewalRamani. 2004. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78:13553-13561.
2. Anastassopoulou, C. G., A. J. Marozsan, A. Matet, A. D. Snyder, E. J. Arts, S. E. Kuhmann, and J. P. Moore. 2007. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog. 3:e79.
3. Arrive, E., M. L. Newell, D. K. Ekouevi, M. L. Chaix, R. Thiebaut, B. Masquelier, V. Leroy, P. V. Perre, C. Rouzioux, and F. Dabis. 2007. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36:1009-1021. (Pubitemid 350018545)
4. Baird, H. A., Y. Gao, R. Galetto, M. Lalonde, R. M. Anthony, V. Giacomoni, M. Abreha, J. J. DeStefano, M. Negroni, and E. J. Arts. 2006. Influence of sequence identity and unique breakpoints on the frequency of intersubtype HIV-1 recombination. Retrovirology 3:91.
5. Baldwin, C. E., R. W. Sanders, Y. Deng, S. Jurriaans, J. M. Lange, M. Lu, and B. Berkhout. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78:12428-12437. (Pubitemid 39458761)
6. Ball, S. C., A. Abraha, K. R. Collins, A. J. Marozsan, H. Baird, M. E. Quiñones-Mateu, A. Penn-Nicholson, M. Murray, N. Richard, M. Lobritz, P. A. Zimmerman, T. Kawamura, A. Blauvelt, and E. J. Arts. 2003. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77:1021-1038. (Pubitemid 36055524)
7. Ballagh, S. A., V. Brache, C. Mauck, M. M. Callahan, L. Cochon, A. Wheeless, and T. R. Moench. 2008. A phase I study of the functional performance, safety and acceptability of the BufferGel Duet. Contraception 77:130-137.
8. Bjo̊rndal, A., H. Deng, M. Jansson, J. R. Fiore, C. Colognesi, A. Karlsson, J. Albert, G. Scarlatti, D. R. Littman, and E. M. Fenyö. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487. (Pubitemid 27391688)
9. Catasti, P., E. M. Bradbury, and G. Gupta. 1996. Structure and polymorphism of HIV-1 third variable loops. J. Biol. Chem. 271:8236-8242. (Pubitemid 26108655)
10. Chen, Z., P. Zhou, D. D. Ho, N. R. Landau, and P. A. Marx. 1997. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J. Virol. 71:2705-2714. (Pubitemid 27119907)
11. Cormier, E. G., and T. Dragic. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76:8953-8957.
12. Hsu, M., J. M. Harouse, A. Gettie, C. Buckner, J. Blanchard, and C. Cheng-Mayer. 2003. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIVSF162P3 maps to envelope gp120. J. Virol. 77:989-998.
13. Hu, J., M. B. Gardner, and C. J. Miller. 2000. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74:6087-6095. (Pubitemid 30412980)
14. Huang, C. C., M. Tang, M. Y. Zhang, S. Majeed, E. Montabana, R. L. Stanfield, D. S. Dimitrov, B. Korber, J. Sodroski, I. A. Wilson, R. Wyatt, and P. D. Kwong. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
15. Keele, B. F., E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, and G. M. Shaw. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105:7552-7557.
16. Ketas, T. J., S. E. Kuhmann, A. Palmer, J. Zurita, W. He, S. K. Ahuja, P. J. Klasse, and J. P. Moore. 2007. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 364:281-290.
17. Kilmarx, P. H., K. Blanchard, S. Chaikummao, B. A. Friedland, N. Srivirojana, C. Connolly, P. Witwatwongwana, S. Supawitkul, P. A. Mock, T. Chaowanachan, and J. Tappero. 2008. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex. Transm. Dis. 35:226-232.
18. Kilmarx, P. H., J. H. van de Wijgert, S. Chaikummao, H. E. Jones, K. Limpakarnjanarat, B. A. Friedland, J. M. Karon, C. Manopaiboon, N. Srivirojana, S. Yanpaisarn, S. Supawitkul, N. L. Young, P. A. Mock, K. Blanchard, and T. D. Mastro. 2006. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J. Acquir. Immune Defic. Syndr. 43:327-334.
19. Lalonde, M. S., R. M. Troyer, A. R. Syed, S. Bulime, K. Demers, F. Bajunirwe, and E. J. Arts. 2007. A sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J. Clin. Microbiol. 45:2604-2615. (Pubitemid 47295494)
20. Landovitz, R. J., J. B. Angel, C. Hoffmann, H. Horst, M. Opravil, J. Long, W. Greaves, and G. Fatkenheuer. 2008. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 198:1113-1122.
21. Lederman, M. M., R. S. Veazey, R. Offord, D. E. Mosier, J. Dufour, M. Mefford, M. Piatak, Jr., J. D. Lifson, J. R. Salkowitz, B. Rodriguez, A. Blauvelt, and O. Hartley. 2004. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487.
22. Lobritz, M. A., A. J. Marozsan, R. M. Troyer, and E. J. Arts. 2007. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J. Virol. 81:8258-8269. (Pubitemid 47101511)
23. Lu, J., P. Sista, F. Giguel, M. Greenberg, and D. R. Kuritzkes. 2004. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78:4628-4637. (Pubitemid 38501084)
24. Marozsan, A. J., and E. J. Arts. 2003. Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J. Virol. Methods 111:111-120. (Pubitemid 36860038)
25. Marozsan, A. J., D. M. Moore, M. A. Lobritz, E. Fraundorf, A. Abraha, J. D. Reeves, and E. J. Arts. 2005. Differences in the fitness of two diverse wildtype human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J. Virol. 79:7121-7134. (Pubitemid 40684493)
26. Nameki, D., E. Kodama, M. Ikeuchi, N. Mabuchi, A. Otaka, H. Tamamura, M. Ohno, N. Fujii, and M. Matsuoka. 2005. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J. Virol. 79:764-770. (Pubitemid 40053859)
27. Pastore, C., G. R. Picchio, F. Galimi, R. Fish, O. Hartley, R. E. Offord, and D. E. Mosier. 2003. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. 47:509-517. (Pubitemid 36158074)
28. Reeves, J. D., S. A. Gallo, J. L. Miamidian, P.E. Harvey, M. Sharron, S. Pohlmann, J. N. Sfakianos, C.A. Derdeyn, R. Blumenthal, E. Hunter, and R. W. Doms. 2003. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 99:16249-16254.
29. Schwartz, J. L., G. Kovalevsky, J. J. Lai, S. A. Ballagh, T. McCormick, K. Douville, C. K. Mauck, and M. M. Callahan. 2008. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 35:414-419.
30. Simmons, G., P. R. Clapham, L. Picard, R. E. Offord, M. M. Rosenkilde, T. W. Schwartz, R. Buser, T. N. Wells, and A. E. Proudfoot. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279.
31. Skoler-Karpoff, S., G. Ramjee, K. Ahmed, L. Altini, M. G. Plagianos, B. Friedland, S. Govender, A. De Kock, N. Cassim, T. Palanee, G. Dozier, R. Maguire, and P. Lahteenmaki. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987.
32. Strizki, J. M., C. Tremblay, S. Xu, L. Wojcik, N. Wagner, W. Gonsiorek, R. W. Hipkin, C. C. Chou, C. Pugliese-Sivo, Y. Xiao, J. R. Tagat, K. Cox, T. Priestley, S. Sorota, W. Huang, M. Hirsch, G. R. Reyes, and B. M. Baroudy. 2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob.Agents Chemother. 49:4911-4919.
33. Taha, T. E., N. I. Kumwenda, A. Gibbons, R. L. Broadhead, S. Fiscus, V. Lema, G. Liomba, C. Nkhoma, P. G. Miotti, and D. R. Hoover. 2003. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 362:1171-1177.
34. Troyer, R. M., K. R. Collins, A. Abraha, E. Fraundorf, D. M. Moore, R. W. Krizan, Z. Toossi, R. L. Colebunders, M. A. Jensen, J. I. Mullins, G. Vanham, and E. J. Arts. 2005. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J. Virol. 79:9006-9018. (Pubitemid 40934811)
35. Troyer, R. M., M. S. Lalonde, E. Fraundorf, K. R. Demers, F. Kyeyune, P. Mugyenyi, A. Syed, C. C. Whalen, F. Bajunirwe, and E. J. Arts. 2008. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res. Hum. Retrovir. 24:235-250.
36. van de Wijgert, J. H., S. L. Braunstein, N. S. Morar, H. E. Jones, L. Madurai, T. T. Strickfaden, M. Moodley, J. Aboobaker, G. Ndlovu, T. M. Ferguson, B. A. Friedland, C. E. Hart, and G. Ramjee. 2007. Carraguard vaginal gel safety in HIV-positive women and men in South Africa. J. Acquir. Immune. Defic. Syndr. 46:538-546. (Pubitemid 350191046)
37. Veazey, R. S., P. J. Klasse, S. M. Schader, Q. Hu, T. J. Ketas, M. Lu, P. A. Marx, J. Dufour, R. J. Colonno, R. J. Shattock, M. S. Springer, and J. P. Moore. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (London) 438:99-102.
38. Veazey, R. S., M. S. Springer, P. A. Marx, J. Dufour, P. J. Klasse, and J. P. Moore. 2005. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med. 11:1293-1294. (Pubitemid 41752908)
39. Wilson, D. P., P. M. Coplan, M. A. Wainberg, and S. M. Blower. 2008. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc. Natl. Acad. Sci. USA 105:9835-9840.
40. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.
41. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:871-875. (Pubitemid 27391780)